INTRODUCTION
Thrombophilia is defined as a predisposition to thrombosis because of disturbances in hemostatic mechanisms. It may originate from hereditary or acquired causes.
1 Disturbances of anticoagulant mechanisms that occur during pregnancy can cause thrombophilia. This can result in placental insufficiency and abortus.
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Recurrent abortion is the condition that defined as three or more spontaneous consecutive miscarriages at a gestational age of 20 weeks or less. The frequency of recurrent abortion is about 0.5-1% per 100 pregnancy. 9 While the females having pregnancy complications were detected to have thrombophilic defects in a ratio of 49-65%, this frequency was found about 18-22% in normal pregnancies. This make people think that complication risk increases by 3-8 fold, based on thrombophilia. 3, 10, 11 Increased early and late miscarriage risk for females with thrombophilic defects has been reported.
12 Thrombophilia screening tests should be done in cases with venous thromboembolism occurred during pregnancy or puerperium, first and second trimester miscarriages and intrauterine fetal death, however, routine screening is not advised for all pregnancies. 13 It is well known that the frequency of thrombophilic defects would differ among distinct societies.
The aim of this study was to determine the thrombophilic risk factors and their frequency in women that presented to the hematology outpatient clinics with recurrent abortion history and at least one detected thrombophilic defect.
MATERIALS AND METHODS
Forty one women that presented with a history of recurrent abortus and found to have at least one thrombophilic defect during examination were evaluated retrospectively. Patients admitted with spontaneous abortion without any thrombophilic risk factor were not included in the study. Demographic and clinical characteristics of the study group are summarized in Table 1 .Written informed consent was obtained from all patients before drawing the blood samples. The study was carried out in accordance with the Helsinki Declaration.
Patients with oral contraceptive usage and hormone replacement therapy, with prior surgical intervention history of recent date and patients with a diagnosis of myeloproliferative disease, paroxysmal nocturnal hemoglobinuria (PNH), diabetes mellitus, dyslipidemia, chronic liver disease, malignancy, vasculitis, collagenous tissue disease and central venous catheter thrombosis were excluded from the study. Laboratory tests related to thrombophilia were performed at least 3 months after a thrombotic event, at least 15 days after discontinuation of heparin therapy or its derivatives and at least 4 weeks after discontinuation of warfarine derivatives. Positive results were repeated at least once again. No the patients were pregnant at the time of laboratory studies.
In this study, we evaluate antithrombin (AT) activity, protein C (PC) activity, total and free protein S (PS) antigen and activity, activated protein C resistance, factor V Leiden (FVL) G1691A gene mutation, prothrombin 20210A (PTG) gene mutation, methylenetetrahydrofolate reductase (MTHFR) C677T gene mutation, factor VIII (F VIII) levels and antiphospholipid antibodies including APA, anticardiolipin antibodies (ACA) IgG and ACA IgM and finally lupus anticoagulant. Commercial PCR kits (MTHFR LC PCR, QIAGEN) were used to investigate MTHFR C677T gene mutations. Prothrombin G20210A gene mutations and FVL mutations were also detected by using commercial kits (Roche Diagnostics). We used "LightCycler 1.5" ROCHE" real time PCR device in our study. Twelve-hour fasting needed for venous blood sampling and citrated blood specimens were centrifuged at 1500 x g for 15 minutes to measure AT, PC, PS, APC-R, LA, FVIII levels. Citrated samples were stored at -20C while waiting. PC activity, PS activity, AT activity and FVIII levels were examined by commercial kits (Dade Behring) and APC-R was assessed by a Dade Behring proC global kit. BCS instrument (DadeBehring) was used for test analyses. Cut-off values were determined by a laboratory reference range study on 40 healthy individuals and the following ranges were accepted to be normal: 70-140% for protein C activity, 58-127% for protein S activity, 75-125% for AT activity and 70-150% for FVIII activity. Patients with high levels of APTT were examined by LA-sensitive aPTT reagent PTT-LA (Diagnostica Stago) test. Presence of heparin, dysfibrinogenemia, factor inhibitors, intrinsic pathway 
RESULTS
A thrombosis history was documented in 17.1% of the patients (n=7) before the study. Family history for thrombosis was positive for only one patient. The most frequently detected thrombophilic defect was MTHFR 677T gene mutation with a percentage of %53.7 (n=22; 15 heterozygote, 7 homozygote). This ratio was followed by FVL gene mutation with a percentage of 39% (n= 16; 14 heterozygote, 2 homozygote) and PS deficiency with a percentage of19.5% (n= 8). The ratio of patients having more than one concurrent defects (n=22) was 53.7%; 20 of them had two, while the remaining had 3 concurrent defects. Detected concomitant thrombophilic defects in our study group presented with a history of recurrent abortion and their frequency are shown in the Table 1 .
DISCUSSION
Hereditary thrombophilia may cause infarcts secondary to placental vascular thrombosis that results in recurrent miscarriages and intrauterine fetal death. 14 In our study, as well as PC, PS, AT activity deficiency, FVL gene mutation, APC-R, PTG and MTHFR gene mutation; the presence of anticardiolipin antibodies and LA tests were also done for hereditary thrombophilia screening. Homocysteine levels were ruled out of the study because it is affected by too many acquired factors and nutritional status of the patient.
Existing studies showed that FVL gene and PTG mutations were the most frequent risk factors among patients with recurrent fetal loss. Investigation of these two mutations primarily in patients with recurrent miscarriages of unknown origin have been recommended. Also it was reported that FVL gene mutation and PT gene mutation were the most frequent defects that may be together. The ratio for concomitance of two defects was found as 17.6% in our study and this ratio was higher than the previously reported ratios for normal population. 15 In a previous study, it was shown that concomitance of two or more defects together and/or homozygosity of the mutation effects pregnancy more unfavorably, compared to the presence of single hereditary thrombophilic factor. 16 Among our patients, the most frequently observed concomitant defects were MTHFR and FVL gene mutation. Whereas double defects ratio was found to be 48.8%, the total ratio for combined defects was found as 53.7% in our study. Increase of this ratio may be based on the fact that the patients with at least one thrombophilic defect were included in the study. Occurrence of more than one defect concomitantly for approximately half of the patients in our study is compatible with this literature data. The results of investigations about whether MTHFR gene mutation increases the risk for recurrent abortion is still controversial. 17, 18 Whereas the ratio of MTHFR C677T gene mutation among patients with a history of recurrent abortion has been found as 30%, while it was 7% for control group. 19 This data is in concordance with the findings of our study that indicate high levels of MTH-FR gene mutation. In that study, it was shown that MTHFR gene mutation was related to early and late complications of pregnancy.
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Limitation of our study was the lack of control group consisting of healthy subjects had the history of normal pregnancy and the patients presented with recurrent abortus without thrombophilic risk factor.
In conclusion, MTHFR gene mutation may be the most frequent hereditary thrombophilic factor among patients with a history of recurrent abortion in women. It can be suggested that the patients who are presented to hematology outpatient clinics in order to be examined about the etiology of recur- 
